Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 3/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.55 |
| ▸ | IGF1R | P08069 | 7/20 | 0.53 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | CCND3 | P30281 | 2/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26577402 | 0.86 | PAK1 (0.48) | PAK4PAK1IGF1RNEK1NTRK1 | |
| SCHEMBL25289587 | 0.86 | PAK4 (0.73) | PAK4PAK1IGF1RNEK1NTRK1 | |
| SCHEMBL30595311 | 0.86 | PAK4 (0.73) | PAK4PAK1IGF1RNEK1NTRK1 | |
| SCHEMBL26273195 | 0.84 | PAK4 (0.67) | PAK4PAK1IGF1RNEK1NTRK1 | |
| SCHEMBL26577286 | 0.77 | PAK1 (0.66) | PAK4PAK1IGF1RNEK1NTRK1 | |
| SCHEMBL28929468 | 0.77 | IGF1R (0.67) | PAK4PAK1IGF1RNEK1 | |
| SCHEMBL24065116 | 0.77 | IGF1R (0.67) | PAK4PAK1IGF1RNEK1 | |
| SCHEMBL26577316 | 0.75 | PAK1 (0.72) | PAK4PAK1IGF1RNEK1NTRK1 | |
| SCHEMBL26577264 | 0.74 | PAK1 (0.67) | PAK4PAK1IGF1RNEK1NTRK1 | |
| SCHEMBL25293382 | 0.73 | PAK1 (0.65) | PAK4PAK1IGF1RNEK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | PAK4 528/4885PAK1 222/4885IGF1R 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.